UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
Data ReadoutnegativeAMT-130Negative
AI Analysis
Summary
UniQure's AMT-130 gene therapy for Huntington's disease showed less disease slowing at 4-year follow-up than anticipated, causing the stock to decline. UniQure executives defended the results as unprecedented but acknowledged that the natural history control group may underestimate disease progression.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Not Met
Outcome Details
4-year Phase 1/2 data shows less slowing of disease progression than expected
Importance:8/10
Sentiment:
-0.85
gene therapyHuntington's diseaseclinical trialPhase 1/2 datanegative catalyst
Related Companies
Read the original article
Published by BioSpace on September 29, 2026 3:03 PM